Zim LaboratoriesNSE:ZIMLAB -2.32%76 Days Payable is 141.21 as of Mar. 2026, which is 4% below its 10-year median of 146.94. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 923 Drug Manufacturers companies, Zim Laboratories ranks better than 75.08% on this metric.
The historical rank and industry rank for Zim Laboratories's Days Payable or its related term are showing as below:
NSE:ZIMLAB'
s Days Payable Range Over the Past 10 Years
Min: 127.16 Med: 146.94 Max: 173.96
Current: 150.1
During the past 12 years, Zim Laboratories's highest Days Payable was 173.96. The lowest was 127.16. And the median was 146.94.
NSE:ZIMLAB's Days Payable is ranked better than 75.08% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs NSE:ZIMLAB: 150.10
Zim Laboratories's Days Payable
increased
from Mar. 2025 (131.43) to Mar. 2026 (141.21).
It may suggest that Zim Laboratoriesdelayed paying its suppliers.
Zim Laboratories Days Payable Related Terms
Zim Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zim Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a Days Payable of 141.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zim Laboratories and its competitors. This is near median its historical median of 146.94. Over the past decade, Zim Laboratories' Days Payable has ranged from 127.16 to 173.96. According to the industry distribution chart, Zim Laboratories ranks #230 out of 923 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Zim Laboratories' Days Payable too high?
Zim Laboratories' current Days Payable of 141.21 is near median its 10-year median of 146.94. Over the past 10 years, this metric has ranged from a low of 127.16 to a high of 173.96. The Drug Manufacturers industry median Days Payable is 90.98. Zim Laboratories' value of 141.21 is 55.2% above this industry median. Based on the distribution chart, Zim Laboratories ranks #230 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #230 out of 923 companies for Days Payable. This places Zim Laboratories in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Zim Laboratories' value of 141.21 is 55.2% above this benchmark. Historically, Zim Laboratories' own Days Payable has ranged from 127.16 to 173.96 over the past decade. While the company's 10-year median is 146.94 vs. the industry median of 90.98, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Days Payable of 141.21 is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Days Payable is 141.21, which is near median its own 10-year median of 146.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current Days Payable is 141.21, which is near median its 10-year median of 146.94 and 55.2% above the Drug Manufacturers industry median of 90.98. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Days Payable is 141.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
Days Payable: 141.21 (near median its 10-year median of 146.94)
GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
Industry Position: 55.2% above the Drug Manufacturers median (#230 of 923)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score
Get the complete analysis for NSE:ZIMLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
